IL-6 (Interleukin-6)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- IL-6 is the primary driver of CRP production — making it upstream of one of longevity medicine's most-used biomarkers. When clinicians measure hsCRP to assess cardiovascular inflammation, they are measuring a downstream product that the liver makes in response to IL-6. Direct IL-6 measurement provides a more mechanistic picture: it identifies the primary inflammatory signal before it produces its hepatic cascades. A person can have elevated IL-6 with still-normal CRP in the early stages of developing chronic inflammation.
- IL-6 directly impairs insulin signaling and contributes to insulin resistance. Beyond its role in inflammation, IL-6 has direct metabolic effects. Chronically elevated IL-6 activates SOCS3 (suppressor of cytokine signaling 3), which inhibits insulin receptor signaling and reduces insulin sensitivity in muscle, liver, and adipose tissue. This creates a bidirectional relationship: adipose tissue (particularly visceral fat) secretes IL-6, which impairs insulin sensitivity, which promotes further fat accumulation and more IL-6 production. This loop is a mechanistic driver of metabolic syndrome.
- Visceral adipose tissue is the primary source of chronic IL-6 elevation in otherwise healthy adults. Adipocytes — fat cells — express and secrete IL-6, and visceral (intra-abdominal) fat is metabolically much more active than subcutaneous fat. The chronic low-grade inflammation associated with obesity and metabolic syndrome is substantially attributable to visceral adipose tissue IL-6 secretion. This is one mechanistic reason why reducing visceral fat (through diet, exercise, and weight management) so consistently improves inflammatory markers.
- IL-6 has a context-dependent dual role — it is anti-inflammatory during acute exercise and pro-inflammatory in chronic metabolic disease. Skeletal muscle releases IL-6 during exercise in large quantities — this exercise-derived IL-6 (sometimes called myokine IL-6) has anti-inflammatory effects and is part of the beneficial signaling that makes exercise protective. Chronic low-level IL-6 from adipose tissue and inflammatory cells has the opposite effect. This distinction explains why exercise reduces systemic inflammation despite transiently elevating IL-6 — the source, context, and duration of elevation determine the downstream effect.
- IL-6 is sensitive to day-to-day variability — stable health states and consistent testing conditions are needed for reliable interpretation. IL-6 rises dramatically during acute illness, after vigorous exercise, after surgery, and with psychological stress. Even poor sleep raises IL-6. Testing during or shortly after any of these states will produce elevated readings that reflect the acute perturbation rather than baseline chronic inflammatory status. For meaningful longevity monitoring, test in a stable state, at least 2–3 days after any illness or intense exercise, with adequate sleep in the preceding nights.
Inflammaging: The Slow Burn Behind Cardiovascular Disease, Metabolic Dysfunction, and Cognitive Decline
One of the most important concepts in longevity medicine is inflammaging — the term coined by immunologist Claudio Franceschi in 2000 to describe the chronic, low-grade, sterile inflammatory state that accumulates with biological aging and is causally linked to virtually every major age-related disease.
Inflammaging is not the acute inflammation of an infection or injury, which is tightly regulated, purposeful, and self-resolving. It is persistent, low-amplitude inflammatory signaling that operates below the threshold of obvious symptoms but continuously damages tissues, impairs cellular function, and drives pathology across organ systems. The mechanisms are multiple: cellular senescence (senescent cells secrete inflammatory factors in the SASP — the senescence-associated secretory phenotype), visceral adipose tissue expansion, gut microbiome dysbiosis with increased bacterial translocation, mitochondrial dysfunction, and epigenetic changes that shift immune cells toward pro-inflammatory phenotypes.
IL-6 is a central mediator of this process. It is the primary inducer of the hepatic acute-phase response (producing CRP, fibrinogen, and other markers), a direct activator of JAK-STAT signaling that drives endothelial dysfunction and atherosclerosis, and a bidirectional link between adipose tissue and systemic metabolic dysfunction. Measuring IL-6 alongside hsCRP provides visibility into both the cytokine source and its downstream hepatic output — a more complete picture than either marker alone.
IL-6 vs. hsCRP: What Each Measures and Why Both Matter
hsCRP is the standard inflammatory marker in cardiovascular risk assessment, with extensive outcome data and well-standardized assays. IL-6 is less commonly ordered in routine clinical care but has several properties that make it complementary rather than redundant.
Mechanistic position: IL-6 is a primary driver of CRP production. Elevated hsCRP almost always reflects elevated IL-6 upstream. But elevated IL-6 does not always produce elevated hsCRP immediately — the hepatic production of CRP takes hours and is modulated by other factors. In early or mild chronic inflammation, IL-6 may be elevated when CRP is still normal.
Independent predictive value: Large prospective studies have found that IL-6 predicts cardiovascular events and all-cause mortality independently of CRP, with effect sizes comparable to traditional risk factors. The Interleukin-6 Receptor Mendelian Randomization Collaboration — a genetic approach to establishing causality — found that IL-6 receptor blockade mimicry was associated with lower cardiovascular risk, strongly supporting a causal rather than merely associative role. 1
Metabolic information: IL-6 directly impairs insulin signaling (through SOCS3 inhibition of insulin receptor substrate proteins), providing metabolic information that CRP does not. Elevated IL-6 in a person with borderline fasting insulin or HbA1c adds biological plausibility to the metabolic concern.
| IL-6 Level | Status | Action |
|---|---|---|
| < 1.5 pg/mL | Longevity optimal | Maintain anti-inflammatory lifestyle |
| 1.5–3.0 pg/mL | Mildly elevated | Review sleep, exercise, diet, body composition |
| 3.0–7.0 pg/mL | Elevated chronic inflammation | Prioritize lifestyle intervention; evaluate metabolic drivers |
| > 7.0 pg/mL | Significantly elevated | Rule out acute illness; clinical evaluation for inflammatory conditions |
| Range Type | Value (pg/mL) | Notes |
|---|---|---|
| Standard Clinical Range | < 7.0 pg/mL (general reference); < 2.0 pg/mL (many longevity-focused labs) | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 1.5 pg/mL |
Associated with reduced all-cause mortality and extended healthspan.
Standard clinical reference ranges for IL-6 vary between laboratories and assay methods, and context-dependent interpretation is important. A value below 2.0 pg/mL is generally considered low-risk in the absence of acute illness. Values between 2.0 and 7.0 pg/mL represent a range where chronic lifestyle-driven inflammation should be evaluated and addressed. IL-6 is exquisitely sensitive to acute illness — even a mild infection, minor surgery, or intense exercise in the preceding 48 hours will elevate IL-6 significantly. Testing should be done in a stable, non-acutely-ill state. Unlike hsCRP, which is typically reported in mg/L and has well-standardized assays, IL-6 assays have more inter-laboratory variability. Trend tracking is particularly valuable for this marker.
|
Already have your results? See what your IL-6 (Interleukin-6) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
If I already test hsCRP, do I need IL-6?
For most people doing a standard longevity panel, hsCRP is the primary inflammatory marker and provides good clinical utility — it is well-standardized, inexpensive, and has extensive outcome data backing its use. IL-6 adds value in specific situations: when hsCRP is elevated and you want to understand the upstream driver; when hsCRP is normal but there are other metabolic or lifestyle factors suggesting chronic inflammation; or when you want a more mechanistically complete picture of cardiovascular inflammatory risk. Large prospective studies — including the PREDICT-2 cohort and multiple cardiovascular risk analyses — have found that IL-6 predicts cardiovascular events and mortality independently of CRP, even in analyses that adjust for CRP. This independent predictive value is the argument for including it. In practice, running IL-6 alongside hsCRP and fibrinogen provides a more complete inflammatory picture than any single marker alone.
What lifestyle factors most strongly drive elevated IL-6?
Visceral adiposity is the dominant driver of chronically elevated IL-6 in otherwise healthy adults — visceral fat secretes substantially more IL-6 than subcutaneous fat. Beyond body composition, sleep quality is a powerful IL-6 modulator: sleep deprivation (even a single night of poor sleep) measurably elevates IL-6 the following day, and chronic sleep restriction drives sustained elevation. Sedentary behavior independently predicts higher IL-6 beyond its effects on body composition. Highly processed dietary patterns (high refined carbohydrate, high trans fat, low fiber) are associated with elevated IL-6; Mediterranean-pattern diets are associated with lower IL-6. Psychological stress (chronic work stress, social isolation, anxiety) elevates IL-6 through the hypothalamic-pituitary-adrenal axis. Periodontal disease and gut dysbiosis also contribute chronic bacterial translocation products that drive macrophage IL-6 secretion.
Why does exercise temporarily raise IL-6 but reduce chronic inflammation over time?
This apparent paradox is well explained by the dual role of IL-6 as both a myokine (muscle-derived signaling molecule) and a cytokine. During aerobic exercise, contracting skeletal muscle releases large amounts of IL-6 — this exercise-induced IL-6 spikes to levels 100× above baseline during prolonged endurance exercise and returns to baseline within a few hours afterward. This myokine IL-6 has metabolic and anti-inflammatory effects: it promotes glucose uptake, increases fat oxidation, and triggers the release of anti-inflammatory cytokines including IL-10 and IL-1 receptor antagonist. The net effect is a transient inflammatory peak followed by an anti-inflammatory rebound. Regular exercise training, through these repeated hormetic stimuli, reduces the baseline chronic inflammatory state — adipose tissue mass falls, insulin sensitivity improves, and resting IL-6 (from adipocytes and inflammatory cells) declines. The practical implication is that testing IL-6 immediately after exercise will give misleadingly elevated results — wait at least 24–48 hours after intense exercise before drawing the sample.
What IL-6 level should prompt clinical concern?
In the context of stable health, a single fasting IL-6 above 7 pg/mL warrants attention and repeat testing to confirm it's not reflecting an acute subclinical inflammatory event. A persistently elevated IL-6 above 7 pg/mL in the absence of acute illness or injury should prompt evaluation for inflammatory conditions, metabolic syndrome, periodontal disease, undetected infection, or autoimmune pathology. Values in the 2–7 pg/mL range represent elevated chronic inflammatory burden that correlates with increased cardiovascular risk in population studies — the appropriate response is lifestyle intervention targeting the primary drivers (visceral adiposity, sleep quality, physical inactivity) rather than immediate medication. In clinical practice, IL-6 is used in combination with other inflammatory markers (hsCRP, fibrinogen, white blood cell differential) and metabolic markers to contextualize the finding.